NorthWest Biotherapeutics Inc (NWBO)

[pqr]

VI thanks for your comments. I understand why Merck would want exclusivity but not why NWBO would permit that. Money, sure, but that assumes that a single licensee is going to pay P/S or royalties at so much higher a rate as to be more profitable than revenue from licensing multiple CI producers. And even if that were possible, which i doubt, I do not see current management agreeing to limit the availability of DC vax for grubby money (assuming manufacturing capacity being sufficient for multiple licensees). I can agree with you that Merck is likely to be the first, but not exclusive, licensee. GLTA